Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (Nasdaq: RVMD) will present updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma at AACR 2026.
As of Dec 1, 2025, daraxonrasib plus gemcitabine/nab-paclitaxel (n=40) showed a confirmed ORR 58% and 6-month PFS estimate 84%. Daraxonrasib monotherapy (n=40) showed ORR 47% and 6-month PFS 71%. Safety was described as manageable; median PFS and OS were not mature. The company says these data support ongoing Phase 3 evaluation, and the company recently reported RASolute 302 met primary and key secondary endpoints including PFS and OS.
Revolution Medicines (Nasdaq: RVMD) will present preclinical data for RM-055 at the AACR Annual Meeting on April 21, 2026, showing a novel catalytic RAS(ON) mechanism that accelerates hydrolysis of mutant RAS-GTP to RAS-GDP.
In preclinical models, RM-055 drove deep, durable regressions across KRAS G12 pancreatic, NSCLC, and colorectal xenografts, including tumors that had escaped prior RAS inhibitors, and preferentially suppressed mutant tumors versus normal tissues.
Revolution Medicines (NASDAQ: RVMD) will present detailed Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC) at the 2026 ASCO Annual Meeting.
The company reported topline results showing daraxonrasib met all primary and key secondary endpoints, with statistically significant improvement in progression-free survival and overall survival versus standard chemotherapy. The plenary presentation is May 31, 2026 at 3:21 PM CDT in McCormick Place, Hall B1.
Revolution Medicines (Nasdaq: RVMD) presented updated Phase 1 (RMC-9805-001) data for zoldonrasib, a KRAS G12D-selective oral inhibitor, at AACR 2026 on April 19, 2026. Data (cutoff Dec 1, 2025) included 40 safety-evaluable NSCLC patients at 1,200 mg daily and an efficacy subset (n=27) with prior checkpoint inhibitor and platinum chemotherapy.
Key results: confirmed objective response rate 52%, disease control rate 93%, median PFS 11.1 months, median duration of response not yet estimable, and manageable safety with Grade 3 TRAEs in 13%.
Revolution Medicines (Nasdaq: RVMD) closed concurrent upsized public offerings on April 17, 2026, raising approximately $2,225.0 million gross and an estimated $2,137.2 million net. The transactions included 12,147,887 common shares at $142.00 per share and $500.0 million of 0.50% convertible senior notes due 2033.
The notes carry a 0.50% coupon, an initial conversion rate of 5.0302 shares per $1,000 principal (≈$198.80 per share), and various conversion, redemption and repurchase provisions. Proceeds are for general corporate purposes, including R&D and potential commercialization expenses.
Revolution Medicines (NASDAQ:RVMD) priced concurrent offerings raising approximately $2.0 billion in aggregate: 10,563,381 shares of common stock at $142.00 per share (~$1.5 billion gross) and $500.0 million aggregate principal of 0.50% convertible senior notes due 2033.
Common settlement is scheduled April 16, 2026 and note settlement April 17, 2026. Net proceeds are estimated at ~$1,435.0 million from the common offering and ~$486.8 million from the note offering, for general corporate purposes.
Revolution Medicines (NASDAQ:RVMD) announced proposed public offerings of $750 million of common stock and $250 million aggregate principal amount of convertible senior notes due 2033, with underwriter overallotment options of $112.5 million and $37.5 million, respectively.
The notes will be senior unsecured, accrue interest semi-annually, be convertible under specified circumstances, and may be redeemable after May 6, 2030. Net proceeds are for general corporate purposes including R&D and commercialization expenses.
Revolution Medicines (NASDAQ:RVMD) reported positive topline Phase 3 RASolute 302 results in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib oral once-daily met all primary and key secondary endpoints, showing median overall survival of 13.2 months vs. 6.7 months for chemotherapy (HR 0.40, p < 0.0001).
The company plans global regulatory submissions including a U.S. New Drug Application under a Commissioner’s National Priority Voucher and will present full data at ASCO 2026.
Revolution Medicines (NASDAQ:RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of daraxonrasib for previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
The randomized, open-label study compares daraxonrasib as monotherapy and combined with gemcitabine plus nab-paclitaxel versus standard-of-care gemcitabine and nab-paclitaxel, enrolling patients irrespective of tumor RAS genotype. Primary endpoints are progression-free survival and overall survival. Daraxonrasib is being evaluated in four global Phase 3 registrational trials, including three in PDAC and one in NSCLC.
Revolution Medicines (Nasdaq:RVMD) will present nine oral and poster presentations at the AACR Annual Meeting, April 17–22, 2026 in San Diego. Highlights include Phase 1 zoldonrasib (G12D) data in KRAS G12D NSCLC (plenary) and Phase 1/2 daraxonrasib datasets in first-line metastatic PDAC (mini-symposium).
Presentations also cover a new class of catalytic RAS(ON) inhibitors addressing emergent resistance and multiple preclinical and clinical RAS(ON) research topics.